NVLPF (Nova Leap Health) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


NVLPF Nova Leap Health Corp NVLPF
50 GF Score
Price $0.25
GF Value $0.19
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nova Leap Health Research & Development?

Nova Leap Health NVLPF 50 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates NVLPF with a GF Score™ of 50/100 and a GF Value™ of $0.19 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nova Leap Health's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Nova Leap Health  (OTCPK:NVLPF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nova Leap Health Research & Development Related Terms

Nova Leap Health Research & Development Historical Data

* Premium members only.

The historical data trend for Nova Leap Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Leap Health Research & Development Chart

Nova Leap Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nova Leap Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NVLPF
50GF Score
Nova Leap Health Corp NVLPF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nova Leap Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Nova Leap Health (NVLPF) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Nova Leap Health and its competitors.
Is Nova Leap Health's Research & Development too high?
Nova Leap Health's current Research & Development is $0.00 Mil. Overall, Nova Leap Health has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nova Leap Health's Research & Development compare to HCA and THC?
Nova Leap Health's Research & Development of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nova Leap Health and its competitors. Nova Leap Health's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Leap Health stock overvalued right now?
Based on GuruFocus' analysis, Nova Leap Health (NVLPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.19, compared to a current price of $0.25 — trading 29.7% above its estimated fair value. The current Research & Development is $0.00 Mil. Nova Leap Health's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nova Leap Health (NVLPF), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Leap Health (NVLPF) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Leap Health stock appears to be overvalued. The current stock price of $0.25 is trading 29.7% above its estimated GF Value™ of $0.19. GuruFocus considers Nova Leap Health to be Modestly Overvalued.

Key valuation signals for NVLPF:

  • Research & Development: $0.00 Mil
  • GF Value™: $0.19 vs. price of $0.25 (29.7% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the NVLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Leap Health Business Description

Other Exchanges NLH:Canada
Address 7071 Bayers Road, Suite 3006, Halifax, NS, CAN, B3L 2C2
Nova Leap Health Corp operates in the healthcare industry. The company is a provider of home and home health care services to clients..The principal business activities of the company and its subsidiaries are to provide skilled and non-medical home care to clients. Its service offerings include meal preparation, housekeeping, transportation, personal care, and medication reminders. Its segments comprise Canadian and U.S. operations. The company derives a majority of its revenue from the United States.
50GF Score

Get the complete analysis for NVLPF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.19
GF Value